target
viral
antigen
proteosom
degrad
previous
propos
mean
immunogen
augment
howev
util
modifi
unstabl
antigen
may
insuffici
potent
tcell
crosspresent
apc
mechan
requir
high
level
antigen
protein
therefor
hypothes
recombin
vaccin
util
combin
proteosomesensit
proteosomeresist
version
antigen
primeboost
regimen
may
provid
effici
ctl
respons
address
hypothesi
util
conserv
proteosomeresist
influenza
viru
protein
unstabl
version
polypeptid
construct
destroy
structur
via
truncat
short
insert
predict
alphahel
structur
modifi
polypeptid
stabil
presenc
proteosom
inhibitor
strongli
suggest
degrad
via
ubiquitinproteosom
pathway
importantli
homolog
dna
vaccin
mixtur
unstabl
proteosomeresist
wt
form
protein
result
significantli
higher
ctl
activ
vaccin
either
wt
degrad
form
dramat
effect
seen
homolog
immun
mixtur
two
form
regimen
produc
notabl
elev
ctl
respons
compar
vaccin
wt
addit
protein
heterolog
vaccin
util
unstabl
form
prime
wild
type
form
boost
demonstr
signific
augment
ctl
respons
data
indic
combin
proteosomesensit
proteosomeresist
form
antigen
vaccin
advantag
correspond
p
ilyinskii
ilyinskii
curelabcom
shneider
ashneid
curelabcom
viral
protein
produc
infect
cell
degrad
proteosom
result
gener
peptid
structur
featur
major
histocompat
complex
mhc
class
ligand
ubiquitin
ub
proteosom
system
directli
involv
product
peptid
antigen
present
mhci
although
import
question
detail
import
immun
defens
process
elucid
yet
subject
intens
discuss
consider
interest
vaccin
strategi
enhanc
induct
antigen
ag
specif
ctl
via
increas
proteosomedepend
degrad
augment
immunogen
target
gene
specif
abil
induc
ctl
respons
mani
group
attempt
target
gene
interest
proteosom
degrad
much
attent
focus
direct
immun
gene
ubproteosom
degrad
pathway
appear
base
somewhat
distort
pictur
ubdepend
ag
present
underli
rational
target
ag
directli
mhci
pathway
would
provid
higher
densiti
peptidemhci
complex
surfac
apc
involv
induct
ctl
respons
target
ag
rapid
proteosom
degrad
augment
process
mhci
present
enhanc
ctl
respons
enhanc
ctl
respons
support
notion
target
ag
rapid
cytoplasm
degrad
might
use
vaccin
strategi
induct
ctl
desir
although
sever
viral
protein
success
degrad
fusion
proteosomedirect
signal
moreov
mani
set
especi
use
viral
model
even
notic
higher
proteosom
degrad
lead
augment
protect
immun
one
possibl
reason
result
underestim
complex
antigen
present
mechan
recent
demonstr
gener
peptid
mhci
present
may
occur
proteosomeindepend
manner
convers
proteosomedepend
antigen
degrad
import
mhcii
present
mhcii
present
drive
mediat
immun
turn
regul
ctl
respons
sever
experiment
system
includ
dna
immun
influenza
therefor
hypothes
simultan
util
wildtyp
proteosomeresist
viral
protein
proteosomedegrad
form
singl
vaccin
regimen
may
advantag
particular
peptid
result
proteosom
degrad
could
serv
fullsiz
protein
much
effici
antigen
crosspresent
cell
crosspresent
play
major
role
survey
tissu
foreign
antigen
present
tcell
immatur
dendrit
cell
dc
like
acquir
viral
ag
intern
infect
cell
debri
ag
crosspres
either
proteasemedi
proteolysi
phagosom
proteosom
pathway
order
process
effici
presenc
fullsiz
ag
necessari
highli
degrad
unstabl
protein
crosspres
therefor
unlik
suffici
immunogen
known
even
dc
directli
transfect
plasmid
rapid
antigen
degrad
advantag
still
degrad
protein
effici
gener
mhci
peptid
nonapc
cell
may
contribut
stage
immun
respons
develop
util
differ
vector
prime
boost
stage
vaccin
heterolog
primeboost
result
manifest
augment
immunogen
effect
may
connect
gener
memori
cell
function
distinct
phenotyp
particular
dnaprimevir
vectorboost
immun
shown
potent
mani
nonvir
viral
model
includ
influenza
vaccin
either
alon
addit
recent
data
shown
memori
cell
stimul
differ
subset
dc
especi
influenza
infect
model
collect
new
insight
develop
immun
respons
known
data
effici
heterolog
primeboost
vaccin
suggest
differ
form
antigen
eg
proteosom
degrad
addit
proteosom
resist
may
provid
elev
immun
use
simultan
either
combin
sequenti
moreov
propos
protein
resist
proteosom
degrad
least
partial
due
inaccess
threedimension
structur
proteosom
machineri
target
destruct
protein
antigen
nativ
conform
delet
region
crucial
protein
fold
insert
disrupt
element
region
ie
alphahel
structur
may
enough
gener
proteosom
degrad
viral
antigen
chosen
protein
influenza
viru
model
antigen
test
hypothesi
construct
degrad
form
protein
either
truncat
dd
insert
predict
alphahel
stretch
assay
immunogen
primeboost
dna
vaccin
regimen
use
proteosom
degrad
mutant
sequenti
andor
simultan
wildtyp
form
experi
perform
human
embryo
kidney
hek
cell
fulllength
gene
encod
influenza
protein
synthes
genbank
sequenc
access
number
insert
pcdna
vector
invitrogen
carlsbad
ca
usa
sequenc
verifi
sali
site
design
ecori
site
gene
digest
sali
ecori
clone
similarli
treat
pcagg
express
vector
modifi
contain
sali
site
instead
ecori
site
result
delet
pointmut
construct
pcrdirect
sitespecif
mutagenesi
wildtyp
gene
pcr
product
ligat
pcdna
vector
point
mutant
design
incorpor
duplic
dd
insert
alphahel
stretch
see
fig
exact
posit
design
base
crystal
structur
resolv
welldefin
eight
dd
diaminoacid
insert
encod
possibl
four
nucleotid
combin
gacgac
gacgat
gatgac
gatgat
avoid
undesir
recombin
sextanucleotid
util
twice
contain
five
four
nonoverlap
one
except
dd
insert
present
delet
mutant
design
truncat
either
four
ctermin
alphahel
stretch
three
ntermin
alphahel
stretch
delet
mutant
design
truncat
differ
fashion
two
mutant
either
ntermin
rnabind
domain
amino
acid
ctermin
effector
domain
amino
acid
welldefin
structur
biolog
hatag
ypydvpdya
encod
sequenc
ad
gene
enabl
effici
immunolog
detect
upon
sequenc
confirm
mutant
gene
clone
pcagg
vector
similarli
wildtyp
gene
result
nine
plasmid
total
see
fig
fig
plasmid
transfect
hek
cell
confluenc
mm
plate
use
lipofectamin
invitrogen
carsbad
ca
usa
either
hour
overnight
total
plasmid
dna
per
control
cell
transfect
amount
empti
vector
pcagg
hour
transfect
emetin
ad
sampl
taken
wash
pb
indic
time
point
construct
chase
variou
time
period
fall
within
hour
emetin
addit
without
proteosom
inhibitor
cell
homogen
ice
lysi
buffer
dish
nacl
mm
trishcl
ph
edta
triton
proteas
inhibitor
sampl
adjust
equal
total
protein
concentr
run
sdspage
follow
immunoblot
either
monoclon
antiha
cell
signal
beverli
usa
antiha
covanc
princeton
nj
usa
antibodi
immun
combin
ctl
respons
vivo
select
wildtyp
mutant
form
two
three
plasmid
use
concurr
inject
intramuscularli
experiment
mous
balbc
three
time
interv
pb
anim
per
group
differ
plasmid
combin
use
prime
boost
anim
receiv
first
combin
prime
twice
two
boost
bodi
weight
immun
mice
follow
assess
possibl
toxic
immun
dna
compar
pbsinject
anim
six
day
third
dna
vaccin
mice
sacrif
splenocyt
purifi
stimul
total
plate
ml
vitro
cocultiv
ratio
syngen
feeder
splenocyt
infect
influenza
viru
taken
healthi
mice
infect
moi
pfucel
hour
uvinactiv
high
level
express
target
spleen
cell
demonstr
immunoblot
viru
protein
specif
antibodi
previous
describ
splenocyt
isol
mice
infect
intranas
twice
threeweek
interv
subleth
dose
influenza
viru
use
posit
ctl
control
stimul
splenocyt
test
mous
incub
separ
dmem
contain
fc
day
previous
describ
splenocyt
stimul
ctl
activ
measur
day
well
previou
studi
detect
minim
ctl
activ
conserv
protein
influenza
day
dna
immun
cytotox
even
highest
effector
target
ratio
therefor
day
timepoint
select
base
observ
longer
splenocyt
stimul
time
necessari
detect
ctl
activ
upon
dna
vaccin
conserv
protein
influenza
includ
mous
mastocytoma
cell
infect
influenza
viru
moi
pfucel
hr
use
target
cytotox
activ
measur
lactat
dehydrogenas
ldh
releas
cytotox
kit
promega
target
infect
cell
well
mix
dilut
stimul
effector
cell
start
cellswel
incub
volum
hr
ctl
activ
cell
lysi
calcul
follow
formula
experiment
releasespontan
releas
maximum
releasespontan
releas
target
cell
incub
medium
alon
medium
contain
deterg
use
determin
spontan
maximum
ldh
releas
uninfect
cell
use
similar
layout
control
specif
ctlmediat
cell
kill
result
shown
mean
sd
group
four
anim
signific
two
percentag
valu
probabl
p
p
se
differ
pvalu
consid
signific
collect
influenza
viru
mutant
construct
test
metabol
stabil
describ
materi
method
construct
seri
mutant
hypothes
less
proteosomeresist
wildtyp
mutant
bear
either
truncat
ctermini
protein
multipl
dd
insert
hydrophob
amino
acid
stretch
design
destroy
predict
alphahel
structur
fig
similarli
mani
viral
protein
wildtyp
influenza
protein
remark
resist
degrad
show
high
degre
stabil
even
hour
observ
vitro
fig
mutant
similar
stabil
test
form
manifest
notabl
higher
degrad
kinet
fig
two
degradationpron
halflif
hour
spite
unstabl
polypeptid
express
level
similar
polypeptid
effici
stabil
shortterm
treatment
proteosom
inhibitor
fig
furthermor
polypeptid
low
molecular
weight
band
appear
gel
shown
strongli
suggest
degrad
proteosomedepend
stabil
pointmut
invers
correl
number
dd
insert
introduc
sinc
may
potenti
gener
immun
respons
determin
present
fulllength
compar
select
immunogen
studi
vivo
influenza
protein
known
abl
suppress
host
immun
respons
via
varieti
pathway
thu
util
even
partial
function
futur
vaccin
regimen
unlik
therefor
focus
construct
delet
mutant
subsequ
stabil
test
mutant
structur
shown
fig
demonstr
extrem
resist
proteosom
degrad
similar
influenza
detect
decreas
protein
level
even
hour
inhibit
protein
synthesi
fig
two
design
mutant
fig
lane
shown
exhibit
chang
protein
stabil
two
truncat
mutant
fig
lane
fig
markedli
less
stabl
follow
hour
protein
synthesi
inhibit
level
drop
significantli
decreas
even
dramat
fig
case
low
molecular
weight
band
observ
shown
degrad
mutant
block
fig
indic
polypeptid
degrad
proteosomedepend
manner
sinc
collect
sequenc
cover
gene
decid
follow
plasmid
next
round
immunogen
studi
sever
group
mice
immun
parallel
prime
two
boost
plasmid
encod
wildtyp
form
select
proteosomedegrad
form
label
fig
former
repres
latter
compris
equimolar
mixtur
ctl
activ
immun
anim
measur
describ
materi
method
signific
variat
test
group
seen
uninfect
cell
use
nonspecif
target
fig
differ
pattern
observ
influenzainfect
target
util
fig
case
homoallel
tripl
immun
wildtypeencod
plasmid
result
similar
ctl
activ
similar
prime
wildtyp
plasmid
follow
boost
plasmid
encod
modifi
form
label
fig
wildtypemodifi
immun
group
case
introduct
modifi
form
prime
stage
led
notic
increas
ctl
respons
evid
prime
boost
group
statist
signific
increas
effectortotarget
ratio
ratio
group
mixtur
wildtyp
modifi
form
use
stage
latter
regimen
result
statist
signific
augment
ctl
activ
compar
regimen
ratio
compar
homolog
immun
ratio
fig
util
homolog
vaccin
led
statist
signific
elev
ctl
activ
ratio
provid
augment
ctl
immunogen
regimen
anim
immun
combin
plasmid
regimen
result
statist
signific
augment
ctl
activ
one
employ
mixtur
wildtyp
proteosom
degrad
form
stage
group
ctl
activ
anim
immun
plasmid
mixtur
markedli
higher
experiment
group
fig
thu
immun
equimolar
quantiti
plasmid
express
wildtyp
well
modifi
form
result
statist
signific
augment
ctl
respons
choic
conserv
influenza
protein
model
antigen
studi
stem
necess
advanc
current
exist
crossprotect
immun
regimen
influenza
protein
alon
capabl
induct
strong
antiinfluenza
immun
compar
nucleoprotein
np
minor
matrix
protein
present
better
model
assess
current
hypothesi
particular
cytoplasm
np
strongli
nuclear
predominantli
resid
membran
infect
cell
mostli
induc
antibodi
respons
convent
mean
augment
viral
protein
degrad
particularli
effect
novel
avenu
increas
proteosomedepend
degrad
influenza
protein
need
explor
hypothes
high
proteosom
stabil
viral
protein
result
conform
structur
proteosom
steric
incap
process
potenti
immunogen
viral
protein
dramat
hinder
distort
present
mhc
class
molecul
latter
seen
therefor
order
increas
proteosomedirect
degrad
protein
one
may
suggest
delet
structurallyimport
region
insert
disrupt
element
approach
shown
use
sinc
abl
produc
rapidli
degrad
form
influenza
either
introduc
dd
insert
hydrophob
amino
acid
stretch
design
delet
mutant
collect
overlap
like
rapid
degrad
mutant
form
due
increas
suscept
proteosom
importantli
initi
demonstr
extrem
proteosomeresist
fig
fig
allow
us
test
combin
wildtyp
proteosomeresist
modifi
proteosomedegrad
form
protein
antigen
may
result
augment
ctl
respons
dna
vaccin
previous
report
approach
substitut
wildtyp
viral
protein
proteosomedegrad
form
mostli
result
disappoint
hypothes
due
complex
antigen
present
network
combin
proteosomedegrad
resist
form
antigen
protein
may
benefici
proteosomedepend
independ
pathway
immunogen
peptid
gener
elucid
predomin
differ
apc
nonapc
moreov
like
differenti
import
prime
boost
stage
vaccin
therefor
seem
probabl
concurr
util
nondegrad
wildtyp
form
viral
protein
capabl
apc
crosspresent
degrad
counterpart
capabl
effici
mhci
peptid
gener
result
higher
ctl
activ
augment
seen
dna
immun
model
util
mixtur
wildtyp
degrad
form
said
protein
induc
higher
ctl
activ
util
either
form
alon
phenomenon
pronounc
fig
heterolog
primeboost
vaccin
variou
form
use
separ
differ
vaccin
stage
manifest
elev
immunogen
convers
proteosomedegrad
form
appli
prime
stage
result
signific
enhanc
ctl
activ
util
form
boost
stage
advantag
fig
possibl
exact
composit
potent
wildtypedegrad
formutil
vaccin
regimen
determin
individu
medicin
import
antigen
ratio
wildtyp
degrad
form
bear
addit
import
protein
influenza
viru
util
studi
predominantli
model
antigen
plan
test
protect
benefit
immun
variou
combin
two
antigen
togeth
proteosomedegrad
resist
form
influenza
np
protein
np
known
capabl
induc
protect
tcell
respons
influenza
previous
report
protect
benefit
vaccin
regimen
combin
np
success
undertak
may
result
gener
novel
npbase
immunogen
provid
suffici
broad
effect
epitop
gener
alway
featur
reverseengin
vaccin
util
viral
protein
medicin
import
recombin
vaccin
may
advanc
well
ctl
respons
anim
immun
variou
combin
plasmid
encod
wildtyp
modifi
form
describ
text
wildtypemodif
label
subsequ
use
two
differ
plasmid
wildtypemodif
label
simultan
use
balbc
mice
inject
time
interv
differ
plasmid
combin
use
subsequ
first
combin
util
prime
anoth
inject
twice
boost
immun
virusinfect
uninfect
b
cell
use
target
background
ctl
activ
induc
immun
empti
vector
subtract
group
statist
signific
differ
mark
p
